{
    "clinical_study": {
        "@rank": "72387", 
        "acronym": "HORIZON", 
        "arm_group": {
            "arm_group_label": "HLT Transcatheter Aortic Valve System", 
            "arm_group_type": "Experimental", 
            "description": "Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and performance of the HLT System in\n      patients with severe aortic stenosis who present at High Risk for aortic valve replacement\n      surgery."
        }, 
        "brief_title": "HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON", 
        "completion_date": {
            "#text": "March 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Severe Aortic Stenosis", 
            "Aortic Valve Stenosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Aortic Valve Stenosis", 
                "Constriction, Pathologic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 75 years of age or older\n\n          2. Echocardiographic or hemodynamic based evidence of calcific (senile) aortic stenosis\n             with one of the following:  aortic valve EOA <1.0 cm2 or 0.6 cm2/m2 ,  mean aortic\n             valve gradient >40 mmHg or peak aortic valve velocity >4 m/sec\n\n          3. Symptomatology  due to aortic stenosis resulting in a New York Heart Association\n             (NYHA) Functional Classification of II or greater\n\n          4. Aortic valve annular diameter \u2265 21 and \u226423mm measured by MSCT\n\n          5. An STS score \u226510; or Logistic EuroScore I \u2265 15; or a determination by one\n             cardiovascular surgeon and one cardiologist that the co-morbidities not captured by\n             the STS or EuroScore expected to increase the operative mortality risk to > 15%.\n\n          6. Geographically available, willing to comply with follow up and able to provide\n             written informed consent\n\n        Exclusion Criteria:\n\n          1. Congenital unicuspid or bicuspid aortic valve, or noncalcified aortic valve; or valve\n             eccentricity (calcific or otherwise) that in the opinion of the investigator could\n             compromise procedural success.\n\n          2. Pre-existing prosthetic heart valve in any position, or prosthetic ring\n\n          3. Severe (Grade 3 to 4) aortic, mitral or tricuspid valve regurgitation\n\n          4. Moderate to severe mitral stenosis\n\n          5. Myocardial infarction within the past 30 days*\n\n          6. Echocardiographic evidence of intracardiac mass, thrombus or vegetation\n\n          7. LVEF < 30%\n\n          8. Uncontrolled hypertension (i.e. blood pressure at baseline > 140 mmHg systolic; or in\n             the opinion of the investigator cannot be controlled by medical therapy).\n\n          9. Severe pulmonary hypertension with pulmonary systolic pressure greater than\n             two-thirds of systemic pressure\n\n         10. Hemodynamic instability requiring inotropic drug therapy within the past 14 days or\n             mechanical support within the past 6 months*\n\n         11. Untreated clinically significant coronary artery disease requiring revascularization\n\n         12. Presence of significant aortic disease such as atheroma, thrombus, or aneurysm which,\n             in the opinion of the investigator, precludes safe implant delivery\n\n         13. Blood dyscrasias defined as: acute  leukopenia, acute anemia, acute thrombocytopenia,\n             history of bleeding diathesis or coagulopathy\n\n         14. Patient ineligible for or refuses blood transfusions\n\n         15. Unfavorable peripheral vascular anatomy or disease (e.g. severe obstructive\n             calcification, severe tortuosity or small vessels) that would preclude passage of\n             catheters from the femoral arterial access to the aorta as evidenced by peripheral\n             MSCT\n\n         16. Active peptic ulcer or gastrointestinal bleeding within the past 90 days*\n\n         17. Stroke or transient ischemic attack within past 6 months*\n\n         18. Renal insufficiency as demonstrated by a serum creatinine > 2.5 mg/dL or end stage\n             renal disease requiring chronic dialysis\n\n         19. Active infection requiring ongoing treatment\n\n         20. Need for emergent surgery or intervention other than the investigational procedure\n\n         21. Any therapeutic invasive cardiac procedure performed or planned to perform within 30\n             days of the index procedure, (or 6 months for drug eluting coronary stent or\n             biventricular pacemaker implantation)*\n\n         22. Hypersensitivity or contraindication to procedural medication and device materials\n             (e.g. titanium, nickel, pork) which cannot be adequately pre-medicated\n\n         23. Life expectancy < 1 year due to non-cardiac co-morbid conditions\n\n         24. Currently participating in any investigational drug or device studies that may\n             confound the results of this study\n\n         25. History of any cognitive or mental health status that would interfere with study\n             participation\n\n        \"*\"At the time of procedure, if a subject's medical status has changed since enrollment,\n        the subject shall be re-evaluated for eligibility."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "75 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02157142", 
            "org_study_id": "HLT1301"
        }, 
        "intervention": {
            "arm_group_label": "HLT Transcatheter Aortic Valve System", 
            "description": "Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System", 
            "intervention_name": "HLT Transcatheter Aortic Valve System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Severe aortic stenosis", 
            "Aortic valve stenosis", 
            "Transcatheter aortic valve replacement"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "contact": {
                "email": "linkea@medizin.uni-leipzig.de", 
                "last_name": "Axel Linke, MD", 
                "phone": "+49-341-8651427"
            }, 
            "contact_backup": {
                "email": "woif@med.uni-leipzig.de", 
                "last_name": "Felix Woitek, MD", 
                "phone": "+49-341-8651671"
            }, 
            "facility": {
                "address": {
                    "city": "Leipzig", 
                    "country": "Germany", 
                    "zip": "04289"
                }, 
                "name": "University of Leipzig - Heart Center"
            }, 
            "investigator": {
                "last_name": "Axel Linke, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON", 
        "overall_contact": {
            "email": "jing.li@hltmedical.com", 
            "last_name": "Jing Li, PhD", 
            "phone": "763-416-7535"
        }, 
        "overall_contact_backup": {
            "email": "Richard.Schroeder@hltmedical.com", 
            "last_name": "Richard Schroeder", 
            "phone": "763-416-7517"
        }, 
        "overall_official": {
            "affiliation": "University of Leipzig - Herzzcntrum", 
            "last_name": "Axel Linke, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The primary performance endpoint is the Device Success defined as:\nAbsence of procedural mortality AND\nCorrect positioning of a single HLT Valve into the proper anatomical location AND\nIntended performance of the HLT Valve (no prosthesis- patient mismatch and mean aortic valve gradient < 20 mmHg or peak aortic valve velocity < 3 m/sec, AND no moderate or severe aortic valve regurgitation)", 
                "measure": "Primary Performance Endpoint 1: Procedural Device Performance", 
                "safety_issue": "Yes", 
                "time_frame": "Post procedure (day of procedure)"
            }, 
            {
                "description": "The primary safety endpoint is all-cause mortality at 30 days.", 
                "measure": "Primary Safety Endpoint 2: Mortality at 30 days", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02157142"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The HLT Valve performance will be evaluated by the following parameters with echocardiograms obtained at pre-discharge, 1, 6, 12, 24, 36, 48 and 60 months:\nAortic valve effective orifice area (EOA)\nSeverity of aortic valve regurgitation (AR)\nAortic valve gradient", 
                "measure": "Secondary Performance Endpoint 1: Post-procedural Valve Performance", 
                "safety_issue": "No", 
                "time_frame": "pre-discharge (up to 14 days), 1, 6, 12, 24, 36, 48 and 60 months"
            }, 
            {
                "description": "All adverse events will be assessed throughout the 5 year follow up period", 
                "measure": "Secondary Safety Endpoint 2: Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "throughout the 5 year follow up period"
            }
        ], 
        "source": "HLT Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "HLT Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}